-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Monterey Bio Acquisition Co. (NASDAQ:MTRYW) Short Interest Update
Monterey Bio Acquisition Co. (NASDAQ:MTRYW) Short Interest Update
Monterey Bio Acquisition Co. (NASDAQ:MTRYW – Get Rating) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 37,400 shares, a growth of 80.7% from the November 30th total of 20,700 shares. Based on an average daily volume of 18,200 shares, the short-interest ratio is presently 2.1 days.
Monterey Bio Acquisition Stock Performance
MTRYW stock opened at $0.02 on Friday. Monterey Bio Acquisition has a fifty-two week low of $0.02 and a fifty-two week high of $0.41. The business's 50 day moving average price is $0.04 and its two-hundred day moving average price is $0.05.
Get Monterey Bio Acquisition alerts:Institutional Inflows and Outflows
An institutional investor recently bought a new position in Monterey Bio Acquisition stock. Ramius Advisors LLC purchased a new position in Monterey Bio Acquisition Co. (NASDAQ:MTRYW – Get Rating) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 286,110 shares of the company's stock, valued at approximately $27,000.
Monterey Bio Acquisition Company Profile
(Get Rating)Monterey Bio Acquisition Corporation focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to acquire businesses in the biotech industry. The company was formerly known as Chardan FinTech Acquisition Corp.
Featured Articles
- Get a free copy of the StockNews.com research report on Monterey Bio Acquisition (MTRYW)
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
- 3 High-Yield Dividend Stocks to Hold for the Long Haul
- Cal-Maine Posts Record Quarter, Remain CALM Income Investors
- Tesla Stock: What the Bulls and the Bears Are Getting Wrong
Receive News & Ratings for Monterey Bio Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monterey Bio Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
Monterey Bio Acquisition Co. (NASDAQ:MTRYW – Get Rating) was the target of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 37,400 shares, a growth of 80.7% from the November 30th total of 20,700 shares. Based on an average daily volume of 18,200 shares, the short-interest ratio is presently 2.1 days.
蒙特利生物收購有限公司(納斯達克:MTRYW — 獲得評級) 是十二月份短期利益大幅增長的目標.截至 12 月 15 日,總共有 37,400 股短息,較 11 月 30 日共 20,700 股股份增長 80.7%。根據每日平均成交量為 18,200 股,短息比率目前為 2.1 天。
Monterey Bio Acquisition Stock Performance
蒙特利生物收購股票表現
MTRYW stock opened at $0.02 on Friday. Monterey Bio Acquisition has a fifty-two week low of $0.02 and a fifty-two week high of $0.41. The business's 50 day moving average price is $0.04 and its two-hundred day moving average price is $0.05.
五月公司股票在周五開盤 0.02 美元。蒙特雷生物收購擁有五十二周低點 0.02 美元,五十二周高點為 0.41 美元。該企業的 50 天移動平均價格為 0.04 美元,其 200 日移動平均價格為 0.05 美元。
Institutional Inflows and Outflows
機構流入和流出
An institutional investor recently bought a new position in Monterey Bio Acquisition stock. Ramius Advisors LLC purchased a new position in Monterey Bio Acquisition Co. (NASDAQ:MTRYW – Get Rating) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 286,110 shares of the company's stock, valued at approximately $27,000.
一名機構投資者最近在蒙特雷生物收購股票中購買了一個新倉位。拉米烏斯顧問有限責任公司購買了蒙特利生物收購有限公司的新位置。(納斯達克:MTRYW — 獲得評級)在第二季度,根據該公司最近 13F 向證券交易委員會提交的文件。該機構投資者購買了該公司股票 286,110 股,價值約為 27,000 美元。
Monterey Bio Acquisition Company Profile
蒙特利生物收購公司簡介
Monterey Bio Acquisition Corporation focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or related business combination with one or more businesses. It intends to acquire businesses in the biotech industry. The company was formerly known as Chardan FinTech Acquisition Corp.
蒙特雷生物收購公司專注於與一個或多個業務合併,資本證券交易所,資產收購,股票購買,重組或相關業務合併。它打算收購生物技術行業的業務。該公司前身為查丹金融科技收購股份有限公司
Featured Articles
特色文章
- Get a free copy of the StockNews.com research report on Monterey Bio Acquisition (MTRYW)
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
- 3 High-Yield Dividend Stocks to Hold for the Long Haul
- Cal-Maine Posts Record Quarter, Remain CALM Income Investors
- Tesla Stock: What the Bulls and the Bears Are Getting Wrong
- 獲取有關蒙特雷生物收購(MTRYW)的股票新聞網研究報告的免費副本
- 金塔拉治療學是一個隱藏的寶石嗎?
- 你應該熱身 Generac 股票的冬天嗎?
- 3 支長期持有的高收益股票
- 卡爾-緬因州發布創紀錄的季度,保持冷靜收入投資
- 特斯拉股票:公牛和熊出錯了什麼
Receive News & Ratings for Monterey Bio Acquisition Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monterey Bio Acquisition and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收蒙特雷生物收購的新聞和評分 -在下面輸入您的電子郵件地址,以通過 MarketBeat.com 的免費每日電子郵件通訊接收蒙特雷生物收購和相關公司的最新新聞和分析師評級的簡要每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧